Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
DOI:
https://doi.org/10.2340/actadv.v102.4490Keywords:
Pemphigus, IgG4, Rituximab, autoantibodyAbstract
Abstract is missing (Short communication)
Downloads
References
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894.
https://doi.org/10.1016/S0140-6736(19)31778-7 DOI: https://doi.org/10.1016/S0140-6736(19)31778-7
Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci 2001; 26: 55-61.
https://doi.org/10.1016/S0923-1811(00)00158-4 DOI: https://doi.org/10.1016/S0923-1811(00)00158-4
Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O'Leary CE, Payne AS. Br J Dermatol 2012; 167: 1245-1253.
https://doi.org/10.1111/j.1365-2133.2012.11144.x DOI: https://doi.org/10.1111/j.1365-2133.2012.11144.x
Kricheli D, David M, Frusic-Zlotkin M, Goldsmith D, Rabinov M, Sulkes J, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000; 143: 337-342.
https://doi.org/10.1046/j.1365-2133.2000.03659.x DOI: https://doi.org/10.1046/j.1365-2133.2000.03659.x
Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34: 1900-1913.
https://doi.org/10.1111/jdv.16752 DOI: https://doi.org/10.1111/jdv.16752
Golinski ML, Lemieux A, Maho-Vaillant M, Barray M, Drouot L, Schapman D, et al. The diversity of serum anti-DSG3 IgG subclasses has a major impact on pemphigus activity and is predictive of relapses after treatment with rituximab. Front Immunol 2022; 13: 849790.
https://doi.org/10.3389/fimmu.2022.849790 DOI: https://doi.org/10.3389/fimmu.2022.849790
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, et al. Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial. JAMA Dermatol 2020; 156: 545-552.
https://doi.org/10.1001/jamadermatol.2020.0290 DOI: https://doi.org/10.1001/jamadermatol.2020.0290
Boch K, Langan EA, Schmidt E, Zillikens D, Ludwig RJ, Bieber K, et al. Sustained CD19+CD27+ memory B cell depletion after rituximab treatment in patients with pemphigus vulgaris. Acta Derm Venereol 2022; 102: adv00679.
https://doi.org/10.2340/actadv.v102.907 DOI: https://doi.org/10.2340/actadv.v102.907
Koneczny I. Update on IgG4-mediated autoimmune diseases: new insights and new family members. Autoimmun Rev 2020; 19: 102646.
https://doi.org/10.1016/j.autrev.2020.102646 DOI: https://doi.org/10.1016/j.autrev.2020.102646
Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B Cell therapies. Neurotherapeutics 2022; 19: 741-752.
https://doi.org/10.1007/s13311-022-01210-1 DOI: https://doi.org/10.1007/s13311-022-01210-1
Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol 2022; 186: 429-439.
https://doi.org/10.1111/bjd.20782 DOI: https://doi.org/10.1111/bjd.20782
Tavakolpour S, Mahmoudi H, Mirzazadeh A, Balighi K, Darabi-Monadi S, Hatami S, et al. Pathogenic and protective roles of cytokines in pemphigus: a systematic review. Cytokine 2020; 129: 155026.
https://doi.org/10.1016/j.cyto.2020.155026 DOI: https://doi.org/10.1016/j.cyto.2020.155026
Published
How to Cite
License
Copyright (c) 2022 Katharina Boch, Ewan A. Langan, Nina van Beek, Khalaf Kridin, Enno Schmidt, Detlef Zillikens, Ralf J. Ludwig, Christoph M. Hammers, Katja Bieber
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.